Related Experiment Video

Updated: Jun 21, 2026

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

Design of selective Cathepsin inhibitors

Paul A Bethel1, Stefan Gerhardt, Emma V Jones

  • 1RIRA, AstraZeneca, Mereside, Alderley Park, Macclesfield SK10 4TG, UK.

Bioorganic & Medicinal Chemistry Letters
|July 21, 2009
PubMed

Abstract:

A number of molecular recognition features have been exploited in structure-based design of selective Cathepsin inhibitors.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

The Importance of Correct Protein Concentration for Kinetics and Affinity Determination in Structure-function Analysis
19:16

The Importance of Correct Protein Concentration for Kinetics and Affinity Determination in Structure-function Analysis

Published on: March 17, 2010

Related Experiment Videos

Last Updated: Jun 21, 2026

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

The Importance of Correct Protein Concentration for Kinetics and Affinity Determination in Structure-function Analysis
19:16

The Importance of Correct Protein Concentration for Kinetics and Affinity Determination in Structure-function Analysis

Published on: March 17, 2010

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Enzymes02:34

Enzymes

Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.

Articles linked to this work by shared authors, journal, and citation graph.

Fragment-Based Discovery of Potent RNA-Competitive Inhibitors of the DEAH-Box RNA Helicase DHX8.

Journal of medicinal chemistry·2026

Discovery of Selective 17β-HSD13 Inhibitors Containing a Phenol Isostere.

Journal of medicinal chemistry·2026

Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.

British journal of cancer·2026

Characterization of the Immunogenomic Landscape of Ovarian Cancer Uncovers a Distinct Subset of Endometroid Tumors Associated with High CST2 Expression and a Favorable Prognosis.

Cancer research communications·2025

Structural changes shifting the redox potential of the outlying cluster N1a in respiratory complex I.

Structure (London, England : 1993)·2025

Discovery of Novel Isofunctional SARS-CoV‑2 NSP14 RNA Cap Methyltransferase Inhibitors by Structure-Based Virtual Screening.

ACS medicinal chemistry letters·2025

Synthesis, computational and in vitro anti-tubercular activity studies of thiadiazole-linked pyridazinone derivatives.

Bioorganic & medicinal chemistry letters·2026

Design, synthesis, and evaluation of novel 5-aminolevulinic acid and 3-hydroxypyridinone conjugates for enhanced photodynamic therapy in triple-negative breast cancer.

Bioorganic & medicinal chemistry letters·2026

Synthesis and antimalarial activity of novel C30-aminated betulin derivatives.

Bioorganic & medicinal chemistry letters·2026

Discovery of orally available benzimidazole-based STING antagonists with in vivo activity.

Bioorganic & medicinal chemistry letters·2026

Novel salicylamido sulfonamides as CD73 immune checkpoint inhibitors: Synthesis and in vitro biological evaluation.

Bioorganic & medicinal chemistry letters·2026

Design and synthesis of dual-target CDK9-EZH2 inhibitors using a pharmacophore fusion strategy.

Bioorganic & medicinal chemistry letters·2026

Recent Developments and Structure-Activity Relationships of BRAF Inhibitors for Cancer Drug Discovery.

Archiv der Pharmazie·2026

Sequential soxhlet fractionation of Cistus ladanifer L. reveals a polarity-activity gradient: GC-MS profiling, multimechanistic bioactivity, and in silico identification of antifungal and antibacterial lead compounds.

Frontiers in chemistry·2026

Novel Benzofuran Derivatives as SARM1 Inhibitors for Treating Axonal Degeneration.

ACS medicinal chemistry letters·2026

Novel Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer.

ACS medicinal chemistry letters·2026

Structure-Activity Relationship Studies Resulting in the Identification of Potent and Selective Salt-Inducible Kinase Inhibitors.

ACS medicinal chemistry letters·2026

Structural Preferences and ADMET Regulation of Fluorinated Small-Molecule Drugs.

ACS medicinal chemistry letters·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us